Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

10.05.2019 | Lyme Borreliosis

Evaluation of the clinical relevance of vancomycin for the treatment of Lyme disease

Wiener klinische Wochenschrift
M.D. Dr. Gary P. Wormser, M.D. Dr. Alan G. Barbour
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Vancomycin is active in vitro and in vivo in mouse systems against Lyme disease borrelia; however, there are no published data on the efficacy of vancomycin in patients with Lyme disease and no convincing theoretical advantages of vancomycin over the currently used and highly effective orally administered antimicrobial agents, including doxycycline, amoxicillin and cefuroxime axetil. In addition, vancomycin may cause a wide variety of potentially serious adverse effects and requires the placement of an intravenous catheter. It is concluded that vancomycin is a much less attractive option for the treatment of patients with early Lyme disease (or any other manifestation of Lyme disease), compared with the antimicrobials currently being used. Based on available evidence, clinical studies to evaluate the safety and efficacy of vancomycin for Lyme disease cannot be recommended.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel